Emulsion comprising a hydrogel and fat or a fat derivative

Abstract

The present invention relates to an emulsion, a gelled emulsion or a gel, comprising a hydrogel and fat or a fat derivative. In one embodiment, the emulsion further comprises at least one active ingredient, the active ingredient being selected from the group consisting of local anaesthetics, vitamin C derivatives, anti-inflammatories, antioxidants and mixtures thereof. The invention also relates to the method for preparing the emulsions, gelled emulsions or gels according to the invention, characterised in that it comprises the following steps: e) providing fat or a fat derivative; f) providing a hydrogel; g) aseptic mixing of the hydrogel and the fat or fat derivative; h) emulsifying the mixture until an emulsion, a gelled emulsion or a homogeneous gel is obtained. The invention also relates to a kit for preparing an emulsion, a gelled emulsion or a gel of fat or a fat derivative and hyaluronic acid, comprising a cartridge 4 and at least 2 syringes making it possible to ensure the process, and the gel obtained, are sterile.

Description

GEL COMPRISING A HYDROGEL AND FAT OR A FAT DERIVATIVE IN THE FORM OF AN EMULSION

[0001] The present invention relates to a malleable gel comprising a hydrogel and fat or a fat derivative in emulsion form.

[0002] It thus relates to a gelled emulsion comprising a hydrogel and fat or a fat derivative.

[0003] It also relates to an emulsion comprising a hydrogel and fat or a fat derivative.

[0004] Fat or fat derivative means fat for lipofilling, MICROFAT or NANOFAT.

[0005] In one embodiment the fat is lipofilling fat, MICROFAT or NANOFAT.

[0006] Fat for lipofilling is fat made up of fatty tissue removed using a cannula that has not undergone any transformation or alteration.

[0007] MICROFAT is fat made up of fatty tissue removed using a small diameter cannula that has not undergone any transformation or alteration.

[0008] NANOFAT is fat made up of removed fatty tissue that has undergone mechanical action with knives to liquefy it, followed by filtration to obtain a very fluid substance enriched with cells.

[0009] NANOFAT can also be obtained using kits designed to treat adipose tissue to release the stromal vascular fraction from adipose tissue cells.

[0010] In one embodiment, the fat is lipofilling fat.

[0011] In one embodiment the grease is MICROFAT.

[0012] In one embodiment the grease is NANOFAT.

[0013] The emulsion obtained is in the form of a composition as illustrated in example 7, the viscoelastic properties of which are those of a gel whose G' is greater than or equal to 20 Pa.

[0014] In one embodiment, G' is greater than or equal to 30 Pa.

[0015] In one embodiment, G' is greater than or equal to 40 Pa.

[0016] The emulsion according to the invention is therefore a gelled emulsion or a gel.

[0017] In one embodiment, the gel, gelled emulsion, or emulsion according to the invention is characterized in that the hydrogel / fat or fat derivative volume ratio is between 0.5 / 4.5 to 2 / 3.

[0018] In one embodiment, the gel, gelled emulsion or emulsion according to the invention is characterized in that the hydrogel / fat or fat derivative volume ratio is 1 / 4.

[0019] Said hydrogel consists of at least one polysaccharide chosen from the group consisting of hyaluronic acid, keratan, heparin, cellulose, cellulose derivatives (in particular hydroxypropylcellulose, hydroxypropylmethylcellulose, ethylmethylcellulose, carboxymethylcellulose), alginic acid, xanthan, carrageenan, chitosan, chondroitin, heparosan, and their biologically acceptable salts, alone or in a mixture.

[0020] In one embodiment, said polysaccharide is hyaluronic acid.

[0021] In one embodiment, said polysaccharide is hyaluronic acid or one of its salts, alone or in a mixture.

[0022] In one embodiment, said polysaccharide is hyaluronic acid in sodium or potassium salt form.

[0023] In one embodiment, said polysaccharide is hyaluronic acid in sodium salt form.

[0024] In one embodiment, said polysaccharide is non-crosslinked hyaluronic acid or one of its salts, alone or in a mixture

[0025] In one embodiment, said polysaccharide is crosslinked hyaluronic acid or one of its salts, alone or in a mixture.

[0026] In one embodiment, said polysaccharide is crosslinked hyaluronic acid or one of its salts, alone or in a mixture, and in that said crosslinking is carried out by means of at least one crosslinking agent.

[0027] In one embodiment, said polysaccharide is crosslinked hyaluronic acid or one of its salts, alone or in a mixture, and in that said crosslinking is carried out by means of at least one bi- or polyfunctional crosslinking agent.

[0028] In one embodiment, said polysaccharide is crosslinked hyaluronic acid or one of its salts, alone or in a mixture, and in that said crosslinking is carried out by means of at least one bifunctional crosslinking agent being butanedioldiglycidyl ether (BDDE) or 1,2,7,8-diepoxyoctane.

[0029] In one embodiment, said polysaccharide is crosslinked hyaluronic acid or one of its salts, alone or in a mixture, and in that said crosslinking is carried out by means of BDDE.

[0030] In one embodiment, said polysaccharide is crosslinked hyaluronic acid or one of its salts, alone or in a mixture, and in that said crosslinking is carried out by means of a sodium or potassium trimetaphosphate.

[0031] When the polysaccharide and more particularly hyaluronic acid is crosslinked using a crosslinking agent, the crosslinking rate (x) is calculated theoretically using the following formula: number of moles of crosslinking agent introduced into the reaction medium number of moles of repeating units introduced into the reaction medium

[0032] In hyaluronic acid, the repeating unit is a disaccharide unit.

[0033] In one embodiment, the crosslinked hyaluronic acid has a crosslinking rate x of between 0.001 and 0.5.

[0034] In one embodiment, the crosslinked hyaluronic acid has a crosslinking rate x of between 0.01 and 0.4.

[0035] In one embodiment, the crosslinked hyaluronic acid has a crosslinking rate x of between 0.1 and 0.3.

[0036] In one embodiment, the crosslinked hyaluronic acid has a crosslinking ratio x of 0.06.

[0037] In one embodiment, the crosslinked hyaluronic acid has a crosslinking ratio x of 0.07.

[0038] In one embodiment, the crosslinked hyaluronic acid has a crosslinking ratio x of 0.12.

[0039] In one embodiment, said polysaccharide is co-crosslinked hyaluronic acid or one of its salts, alone or in a mixture.

[0040] In one embodiment, said polysaccharide is chemically modified hyaluronic acid by substitution, crosslinked or non-crosslinked, or one of its salts, alone or in a mixture.

[0041] In one embodiment, said polysaccharide is doubly crosslinked hyaluronic acid as described in patent application WO2000 / 046253 in the name of Fermentech medical limited.

[0042] In one embodiment, said polysaccharide is a mixture of hyaluronic acids, or one of their salts, crosslinked and non-crosslinked.

[0043] In one embodiment, said polysaccharide is a mixture of crosslinked hyaluronic acids, or one of their salts.

[0044] In one embodiment, said polysaccharide is a mixture of hyaluronic acids, or one of their salts, crosslinked such as that described in patent application WO2009 / 071697 in the name of the applicant.

[0045] In one embodiment, said polysaccharide is a mixture of hyaluronic acids, obtained by mixing several hyaluronic acids, or one of their salts, of different molecular masses prior to their crosslinking, as described in patent application WO2004092222 in the name of Cornéal industrie.

[0046] In one embodiment, said polysaccharide is hyaluronic acid or one of its salts, substituted by a group providing lipophilic or moisturizing properties, such as for example substituted hyaluronic acids as described in patent application FR2983483 in the name of the applicant. In this application is described a process for the simultaneous substitution and crosslinking of a polysaccharide via its hydroxyl functions, in aqueous phase, characterized in that it comprises the following steps: (i) a polysaccharide is provided in an aqueous medium, (ii) it is placed in the presence of at least one precursor of a substituent, (iii) it is placed in the presence of a crosslinking agent, and (iv) the substituted and crosslinked polysaccharide is obtained and isolated. These process steps can be perfectly implemented within the scope of the present invention.

[0047] In one embodiment, said polysaccharide is hyaluronic acid or one of its salts, grafted with glycerol, for example as described in application WO2017162676 in the name of MERZ.

[0048] In one embodiment, the average molecular weight Mw of the at least one hyaluronic acid is in a range of 0.01 MDa to 5 MDa (0.01 <Mw <5 MDa).

[0049] In one embodiment, the average molecular weight Mw of the at least one hyaluronic acid is in a range of 0.1 MDa to 3.5 MDa (0.1 <Mw <3,5 MDa).

[0050] In one embodiment, the average molecular weight Mw of the at least one hyaluronic acid is in a range of 1 MDa to 3 MDa (1 <Mw <3 MDa).

[0051] In one embodiment, the average molecular mass Mw of the at least one hyaluronic acid is 1 MDa.

[0052] In one embodiment, the average molecular mass Mw of the at least one hyaluronic acid is 3 MDa.

[0053] In one embodiment, the concentration of hyaluronic acid [HA] is between 2 mg / g and 50 mg / g of total weight of said hydrogel.

[0054] In one embodiment, the concentration of hyaluronic acid [HA] is between 4 mg / g and 40 mg / g of total weight of said hydrogel.

[0055] In one embodiment, the concentration of hyaluronic acid [HA] is between 5 mg / g and 30 mg / g of total weight of said hydrogel.

[0056] In one embodiment, the concentration of hyaluronic acid [HA] is between 10 mg / g and 30 mg / g of total weight of said hydrogel.

[0057] In one embodiment, the concentration of hyaluronic acid [HA] is 20 mg / g of total weight of said hydrogel.

[0058] In one embodiment, the concentration of hyaluronic acid [HA] is 14 mg / g of total weight of said hydrogel.

[0059] In one embodiment, the concentration of hyaluronic acid [HA] is 10 mg / g of total weight of said hydrogel.

[0060] In one embodiment, the gel, gelled emulsion or emulsion further comprises at least one active ingredient, said active ingredient being chosen from the group consisting of local anesthetics, vitamin C derivatives, anti-inflammatories, antioxidants, and mixtures thereof.

[0061] In one embodiment the gel, gelled emulsion or emulsion is free of emulsifier, for example as described in patent application WO2011019822 in the name of JOHN HOPKINS.

[0062] In one embodiment, the gel, gelled emulsion or emulsion is free of chemical compounds promoting vascularization (angiogenesis or vasculogenesis) as described in patent application US20120189708 in the name of ALLERGAN.

[0063] In one embodiment, the gel, gelled emulsion or emulsion is free of polymer promoting cell viability or proliferation such as, for example, silk fibers or collagen as described in application US20180055971 in the name of ALLERGAN.

[0064] In one embodiment, the hydrogel is sterilized, that is to say that it undergoes a sterilization step after its preparation, said sterilization step being carried out by heat, by moist heat, by gamma(y) radiation, by accelerated electron beam, or by sterilizing filtration (0.22 pm) in the case of hydrogels based on non-crosslinked hyaluronic acid.

[0065] In one embodiment, said sterilization step is carried out by steam autoclaving.

[0066] In one embodiment, steam autoclaving is carried out at a temperature of 121 to 134°C, for a time appropriate to the temperature.

[0067] In one embodiment, steam autoclaving is carried out at a temperature between 127 and 130°C for a time between 1 and 20 min.

[0068] In one embodiment, the sterilizing value F0 is greater than 1 min at 121°C.

[0069] In one embodiment, said sterilization step is carried out by gamma (γ) irradiation.

[0070] In one embodiment, the method for preparing gels, gelled emulsions or emulsions according to the invention further comprises at least one step of adding at least one active ingredient.

[0071] In one embodiment, the at least one active ingredient is added in powder form.

[0072] In one embodiment, the at least one active ingredient is added as a solution or suspension.

[0073] In one embodiment, the at least one active ingredient is added in the form of a solution or suspension, in a solvent or solution chosen from the group consisting of water, aqueous saline solutions, for example a phosphate buffer solution, for example PBS.

[0074] In one embodiment, the at least one active ingredient is added to the hyaluronic acid.

[0075] In one embodiment, the at least one active ingredient is added after the step of preparing the gels, gelled emulsions or emulsions according to the invention.

[0076] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one active ingredient chosen from the group consisting of local anesthetics, vitamin C derivatives, anti-inflammatories, antioxidants, and mixtures thereof.

[0077] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic.

[0078] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic to obtain a concentration of local anesthetic of between 0.1 and 5%, relative to the total mass of said emulsion.

[0079] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic to obtain a concentration of local anesthetic of between 0.1 and 4%, relative to the total mass of said emulsion.

[0080] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic to obtain a concentration of local anesthetic of between 0.1 and 2%, relative to the total mass of said emulsion.

[0081] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic to obtain a concentration of local anesthetic of between 0.1 and 1%, relative to the total mass of said emulsion.

[0082] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic to obtain a concentration of local anesthetic of between 0.1 and 0.5%, relative to the total mass of said emulsion.

[0083] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic to obtain a local anesthetic concentration of approximately 0.3%, relative to the total mass of said emulsion.

[0084] In one embodiment, the local anesthetic is selected from the group of amino esters.

[0085] In one embodiment, the amino ester is selected from the group consisting of procaine, benzocaine, chloroprocaine and tetracaine in base or salt form, for example in hydrochloride form.

[0086] In one embodiment, the local anesthetic is selected from the group of amino-amides.

[0087] In one embodiment, the amino amide is selected from the group consisting of lidocaine, mepivacaine, prilocaine, articaine, aptocaine, bupivacaine, etidocaine and ropivacaine in base or salt form, for example in hydrochloride form.

[0088] In one embodiment, the local anesthetic is selected from the group of amino ethers.

[0089] In one embodiment, the amino ether is selected from the group consisting of diamocaine and pramocaine in base or salt form, for example in hydrochloride or cyclamate form.

[0090] In one embodiment, the amino ether is selected from the group consisting of lidocaine, mepivacaine, and their salts and isolated isomers.

[0091] In one embodiment, the amino ether is lidocaine.

[0092] In one embodiment, the amino ether is lidocaine or a pharmaceutically acceptable salt thereof.

[0093] In one embodiment, the amino ether is lidocaine hydrochloride.

[0094] In one embodiment, the amino ether is mepivacaine.

[0095] In one embodiment, the amino ether is mepivacaine or a pharmaceutically acceptable salt thereof.

[0096] In one embodiment, the amino ether is selected from the group consisting of racemic mepivacaine hydrochloride, racemic mepivacaine hydrochloride, (r)-mepivacaine hydrochloride, (s)-mepivacaine hydrochloride, (r)-mepivacaine and (s)-mepivacaine, or a pharmaceutically acceptable salt thereof.

[0097] In one embodiment, the amino ether is mepivacaine hydrochloride.

[0098] In one embodiment, the amino ether is (r)-mepivacaine hydrochloride.

[0099] In one embodiment, the amino ether is (s)-mepivacaine hydrochloride. [000100] In one embodiment, the amino ether is racemic mepivacaine hydrochloride. [000101] In one embodiment, the amino ether is (r)-mepivacaine. [000102] In one embodiment, the amino ether is (s)-mepivacaine. [000103] In one embodiment, the amino ether is racemic mepivacaine. [000104] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one amino-ether local anesthetic chosen from the group consisting of lidocaine, mepivacaine, and mixtures thereof. [000105] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being lidocaine. [000106] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being lidocaine to obtain a lidocaine concentration of between 0.1 and 5%, relative to the total mass of said emulsion. [000107] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being lidocaine to obtain a lidocaine concentration of between 0.1 and 4%, relative to the total mass of said emulsion. [000108] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being lidocaine to obtain a lidocaine concentration between 0.1 and 2%, relative to the total mass of said emulsion. [000109] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being lidocaine to obtain a lidocaine concentration of between 0.1 and 1%, relative to the total mass of said emulsion. [000110] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being lidocaine to obtain a lidocaine concentration of between 0.1 and 0.5%, relative to the total mass of said emulsion. [000111] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being lidocaine to obtain a local anesthetic concentration of approximately 0.3%, relative to the total mass of said emulsion. [000112] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being mepivacaine. [000113] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being mepivacaine to obtain a mepivacaine concentration of between 0.1 and 5%, relative to the total mass of said emulsion. [000114] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being mepivacaine to obtain a mepivacaine concentration of between 0.1 and 4%, relative to the total mass of said emulsion. [000115] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being mepivacaine to obtain a mepivacaine concentration of between 0.1 and 2%, relative to the total mass of said emulsion. [000116] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being mepivacaine to obtain a mepivacaine concentration between 0.1 and 1%, relative to the total mass of said emulsion. [000117] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being mepivacaine to obtain a mepivacaine concentration of between 0.1 and 0.5%, relative to the total mass of said emulsion. [000118] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being mepivacaine to obtain a local anesthetic concentration of approximately 0.3%, relative to the total mass of said gel, said gelled emulsion or said emulsion. [000119] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic being dyclonine in base or salt form, for example in hydrochloride form. [000120] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one local anesthetic chosen from the group consisting of chlorobutanol, guafecainol and polidocanol. [000121] In one embodiment, the local anesthetic is chlorobutanol. [000122] In one embodiment, the local anesthetic is guafecainol. [000123] In one embodiment, the local anesthetic is polidocanol. [000124] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory. [000125] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory agent chosen from the group consisting of steroidal and non-steroidal anti-inflammatories. [000126] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory chosen from the group consisting of non-steroidal anti-inflammatories. [000127] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory chosen from the group comprising: salicylate anti-inflammatories, propionic derivatives, indole derivatives, pyrazole derivatives, oxicams and coxibs. [000128] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory agent chosen from the group comprising diclofenac, nimesulfide, niflumic acid, mefenamic acid and nabumetone, alone or as a mixture. [000129] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one salicylated anti-inflammatory chosen from the group comprising diflunisal, benorilate and aspirin, alone or as a mixture. [000130] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory chosen from the group of propionic derivatives comprising alminoprofen, ketoprofen, ibuprofen, naproxen, flurbiprofen and tiaprofenic acid, alone or as a mixture. [000131] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory agent chosen from the group of indole derivatives comprising indomethacin, sulindac and etodolac, alone or as a mixture. [000132] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory chosen from the group of pyrazole derivatives including in particular phenylbutazone. [000133] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory chosen from the group of oxicams comprising piroxicam, tenoxicam and meloxicam, alone or as a mixture. [000134] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory chosen from the group of coxibs comprising celecoxib, etoricoxib and rofecoxib, alone or as a mixture. [000135] In one embodiment, the concentration of non-steroidal anti-inflammatory drugs in the gel, gelled emulsion or emulsion according to the invention is between 0.01 and 2000 mg / g. [000136] In one embodiment, the concentration of non-steroidal anti-inflammatory drugs in the gel, gelled emulsion or emulsion according to the invention is between 0.1 and 1000 mg / g. [000137] In one embodiment, the concentration of non-steroidal anti-inflammatory drugs in the gel, gelled emulsion or emulsion according to the invention is between 0.5 and 500 mg / g. [000138] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one steroidal anti-inflammatory. [000139] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one steroidal anti-inflammatory chosen from the group comprising dexamethasone, prednisolone, corticosterone, budesonide, sulfasalazine, mesalamine, cetirizine, diphenhydramine, antipyrine, methyl salicylate, loratadine, thymol, carvacrol, bisabolol, allantoin, eucalyptol, phenazone (antipyrine), propyphenazone, alone or as a mixture. [000140] In one embodiment, the concentration of steroidal anti-inflammatories in the gel, gelled emulsion or emulsion according to the invention is between 0.01 and 2000 mg / g. [000141] In one embodiment, the concentration of steroidal anti-inflammatories in the gel, gelled emulsion or emulsion according to the invention is between 0.1 and 1000 mg / g. [000142] In one embodiment, the concentration of steroidal anti-inflammatories in the gel, gelled emulsion or emulsion according to the invention is between 0.5 and 500 mg / g. [000143] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory agent chosen from the group consisting of sucrose octasulfate and its salts. [000144] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory agent chosen from the group consisting of sucrose octasulfate and its sodium and potassium salts. [000145] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory water-soluble salt of sucrose octasulfate chosen from the group consisting of alkali metal salts, alkaline earth metal salts, silver salts, ammonium salts, amino acid salts. [000146] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory water-soluble salt of sucrose octasulfate selected from the group consisting of alkali metal salts or alkaline earth metal salts. [000147] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-inflammatory water-soluble salt of sucrose octasulfate chosen from the group consisting of the sodium salt of sucrose octasulfate or the potassium salt of sucrose octasulfate. [000148] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antimicrobial. [000149] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antimicrobial chosen from the group comprising gentamicin, silver sulfadiazine, metronidazole, fucidin, bacitracin, eosin, povidone iodine, copper gluconate, zinc gluconate, manganese gluconate or their salts, alone or as a mixture. [000150] In one embodiment, the concentration of antimicrobials in the gel, gelled emulsion or emulsion according to the invention is between 0.1 and 200 mg / g. [000151] In one embodiment, the concentration of antimicrobials in the gel, gelled emulsion or emulsion according to the invention is between 0.5 and 100 mg / g. [000152] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one glycoside or a glycoside derivative. [000153] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one glycoside or glycoside derivative chosen from the group comprising D-glucopyranose, 1,4 glycoside, esculin, hesperidin, diosmin, arbutin, skimmin or aloin, alone or in mixtures. [000154] In one embodiment, the concentration of glycosides in the gel, gelled emulsion or emulsion according to the invention is between 0.1 and 200 mg / g. [000155] In one embodiment, the concentration of glycosides in the gel, the gelled emulsion or the emulsion according to the invention is between 0.5 and 100 mg / g. [000156] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one tissue moisturizer or regenerator. [000157] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one moisturizer or tissue regenerator chosen from the group consisting of macro-elements. [000158] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one macro-element chosen from the group comprising iron, calcium, copper, zinc, manganese, magnesium or potassium gluconates, trimethylsilanol, trimethylsilanolate, potassium trimethylsilanolate, methylsilanol mannuronate, sodium monoethyltrisilanol orthohydroxybenzoate, alone or as a mixture. [000159] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one tissue moisturizer or regenerator chosen from the group consisting of essential amino acids. [000160] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one essential amino acid chosen from the group comprising isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine, alone or as a mixture. [000161] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one tissue moisturizer or regenerator chosen from the group consisting of semi-essential amino acids. [000162] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one semi-essential amino acid chosen from the group comprising arginine and histidine, alone or as a mixture. [000163] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one tissue moisturizer or regenerator chosen from the group consisting of non-essential amino acids. [000164] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one non-essential amino acid chosen from the group comprising alanine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, proline, serine, tyrosine, alone or as a mixture. [000165] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one moisturizer or tissue regenerator chosen from the group consisting of vitamins. [000166] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one vitamin chosen from the group consisting of retinol, thiamine, riboflavin, nicotinamide, adenine, calcium pantothenate, pyridoxine, inositol, biotin, folic acid, para-aminobenzoic acid, cobalamin, vitamin C, choline chloride, alone or as a mixture. [000167] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one tissue moisturizer or regenerator chosen from the group consisting of nucleic acids. [000168] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one nucleic acid chosen from the group consisting of deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, methylcytosine, alone or as a mixture. [000169] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one tissue moisturizer or regenerator chosen from the group consisting of coenzymes. [000170] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one coenzyme chosen from the group consisting of thiamine pyrophosphate, coenzyme A, FAD, NAD, NADP, UTP, alone or as a mixture. [000171] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one tissue moisturizer or regenerator chosen from the group consisting of deoxythymidine, glutathione, sodium pyruvate, lipoic acid and putrescine, alone or as a mixture. [000172] In one embodiment, the concentration of tissue moisturizers or regenerators in the gel, gelled emulsion or emulsion according to the invention is between 0.01 and 500 mg / g. [000173] In one embodiment, the concentration of tissue moisturizers or regenerators in the gel, gelled emulsion or emulsion according to the invention is between 0.1 and 200 mg / g. [000174] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant. [000175] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant chosen from the group of polyols. [000176] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol chosen from the group consisting of mannitol, sorbitol, propylene glycol, xylitol, glycerol, maltitol, lactitol and erythritol. [000177] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol chosen from the group consisting of mannitol, sorbitol, maltitol and glycerol, alone or as a mixture. [000178] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol chosen from the group consisting of mannitol, sorbitol and maltitol, alone or as a mixture. [000179] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol to obtain a polyol concentration of between 0.1 mg / ml and 50 mg / ml, relative to the total mass of said emulsion. [000180] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol to obtain a polyol concentration of between 5 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000181] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol to obtain a polyol concentration of between 10 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000182] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol to obtain a polyol concentration of between 20 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000183] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol to obtain a polyol concentration of between 30 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000184] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol being mannitol. [000185] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding mannitol to obtain a mannitol concentration of between 5 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000186] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding mannitol to obtain a mannitol concentration of between 10 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000187] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding mannitol to obtain a mannitol concentration of between 20 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000188] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding mannitol to obtain a mannitol concentration of between 30 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000189] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol being sorbitol. [000190] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding sorbitol to obtain a sorbitol concentration of between 5 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000191] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding sorbitol to obtain a sorbitol concentration of between 10 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000192] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding sorbitol to obtain a sorbitol concentration of between 20 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000193] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding sorbitol to obtain a sorbitol concentration of between 30 mg / ml and 40 mg / ml, relative to the total mass of said emulsion. [000194] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol being maltitol. [000195] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one polyol being glycerol. [000196] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding a mixture of mannitol and sorbitol. [000197] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant chosen from the group of vitamin C derivatives. [000198] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant chosen from the group of vitamin C derivatives comprising magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl-2-glucoside, and a mixture thereof. [000199] In one embodiment, said at least one vitamin C derivative is magnesium ascorbyl phosphate. [000200] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant chosen from the group of vitamin E derivatives and tocopherols. [000201] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant chosen from the group of carotenoids and retinoids and their derivatives. [000202] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant chosen from the group of carotenoids and retinoids and their derivatives comprising retinol, retinoic acid, retinal, retinol esters and carotene. [000203] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant chosen from the group of pseudo-tripeptides. [000204] In one embodiment, the pseudo-tripeptide is glutathione. [000205] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant chosen from the group comprising the different forms of coenzyme Q10, ubiquinone or ubiquinol. [000206] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one vitamin. [000207] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one vitamin chosen from the group comprising retinol, thiamine, riboflavin, nicotinamide, dexpenthenol, pyridoxine, ascorbic acid, ergocalciferol, tocopherol, biotin and folic acid alone or as a mixture. [000208] In one embodiment, the concentration of vitamins in an emulsion according to the invention is between 0.01 and 200 mg / g. [000209] In one embodiment, the concentration of vitamins in an emulsion according to the invention is between 0.01 and 100 mg / g. [000210] In one embodiment, the concentration of vitamins in an emulsion according to the invention is between 0.5 and 50 mg / g. [000211] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one amino acid. [000212] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one amino acid chosen from the group consisting of essential amino acids, semi-essential amino acids and non-essential amino acids, alone or as a mixture. [000213] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one amino acid chosen from the group of essential amino acids. [000214] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one essential amino acid chosen from the group comprising Isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan and valine, alone or in mixture. [000215] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one amino acid chosen from the group of semi-essential amino acids. [000216] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one semi-essential amino acid chosen from the group comprising arginine and histidine, alone or as a mixture. [000217] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one amino acid chosen from the group of non-essential amino acids. [000218] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one non-essential amino acid chosen from the group comprising alanine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, proline, serine, tyrosine, alone or as a mixture. [000219] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one amino acid chosen from the group comprising hydroxyproline, taurine and ornithine, alone or as a mixture. [000220] In one embodiment, the concentration of amino acids in an emulsion according to the invention is between 0.01 and 150 mg / g. [000221] In one embodiment, the concentration of amino acids in an emulsion according to the invention is between 0.01 and 100 mg / g. [000222] In one embodiment, the concentration of amino acids in an emulsion according to the invention is between 0.5 and 50 mg / g. [000223] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one vasoconstrictor. [000224] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one vasoconstrictor chosen from the group comprising naphazoline, epinephrine, methoxamine, methylnorepinephrine, norepinephrine, oxymethazoline, phenylephrine, pseudoephedrine, synephrine, cirazoline and xylometazoline. [000225] In one embodiment, the concentration of vasoconstrictors in an emulsion according to the invention is between 0.01 and 3 mg / g. [000226] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one vasodilator. [000227] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one vasodilator chosen from the group comprising adenosine, nicotinic acid, minoxidil and diazoxide, alone or as a mixture. [000228] In one embodiment, the concentration of vasodilators in the gel, gelled emulsion or emulsion according to the invention is between 0.01 and 10 mg / g. [000229] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-hemorrhagic or hemostatic agent. [000230] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one anti-hemorrhagic or hemostatic agent chosen from the group comprising aminocaproic acid or tranexamic acid, alone or as a mixture. [000231] In one embodiment, the concentration of anti-hemorrhagic or hemostatic agents in the gel, gelled emulsion or emulsion according to the invention is between 0.01 and 5 mg / g. [000232] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant and at least one local anesthetic. [000233] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant chosen from the group of polyols and at least one local anesthetic chosen from the group of amino-amides. [000234] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant, at least one vitamin and at least one tissue regenerator. [000235] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one amino acid, at least one vitamin and at least one tissue regenerator. [000236] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one antioxidant, at least one amino acid, at least one vitamin and at least one tissue regenerator. [000237] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one active agent chosen from the group consisting of heat-sensitive active agents. [000238] In one embodiment, the at least one heat-sensitive active agent is added during the step of preparing the gels, gelled emulsions or emulsions according to the invention, namely during the step of mixing the hydrogel and the fat or fat derivative. [000239] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding a so-called heat-sensitive active ingredient of natural origin. [000240] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding a so-called heat-sensitive active ingredient of synthetic origin. [000241] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one heat-sensitive active ingredient chosen from the group consisting of peptides, hormones, proteins, growth factors, antibodies and vitamins, alone or as a mixture. [000242] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one heat-sensitive active agent chosen from the group consisting of peptides. [000243] In one embodiment, the added thermosensitive active ingredient is a peptide. [000244] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one thermosensitive active ingredient chosen from the group consisting of hormones. [000245] In one embodiment, the added heat-sensitive active is a hormone. [000246] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one heat-sensitive active agent chosen from the group consisting of proteins. [000247] In one embodiment, the added thermosensitive active ingredient is a protein. [000248] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one thermosensitive active ingredient chosen from the group consisting of growth factors. [000249] In one embodiment, the added heat-sensitive active is a growth factor. [000250] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one heat-sensitive active agent chosen from the group consisting of antibodies. [000251] In one embodiment, the added heat-sensitive active ingredient is an antibody. [000252] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one heat-sensitive active ingredient chosen from the group consisting of vitamins. [000253] In one embodiment, the vitamins are selected from the group comprising retinol, thiamine, riboflavin, nicotinamide, dexpanthenol, pyridoxine, ascorbic acid, ergocalciferol, tocopherol, biotin and folic acid alone or in a mixture. [000254] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one mesotherapy ancillary chosen from the group consisting of tissue inducers. [000255] In one embodiment, the added mesotherapy ancillary is a tissue inducer. [000256] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one mesotherapy ancillary selected from the group consisting of calcium hydroxyapatite, poly-L-lactic acid (PLLA), polycaprolactone, polymethyl methacrylate (PMMA) and / or polyalkylamide. In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one vehicle of the tissue inducers. [000257] In one embodiment, the method for preparing an emulsion, a gelled emulsion or a gel according to the invention further comprises at least one step of adding at least one vehicle of the tissue inducers chosen from the group consisting of glycerin, carboxymethylcellulose, glycerol, polyethylene glycol, or dextran. [000258] The applications targeted are more particularly the following pathologies or treatments: - Aesthetic injections in the face: mesotherapy, skin rejuvenation, filling of wrinkles and fine lines, imperfections and skin defects or volume (cheekbones, chin, lips, or any other part of the face, head or scalp); - Improved tissue trophicity. Improved microvascularization, type II collagen, and tissue thickness. - Body volume injections: breast and buttock augmentation, G-spot augmentation, vaginoplasty, labia reconstruction, penis enlargement; or any body area requiring improvement in fat volume or skin trophicity: hands and limbs, heels and support areas, buttocks and intimate areas. - Treatment of osteoarthritis, injection into the joint to replace or supplement deficient synovial fluid; - Periurethral injection for the treatment of urinary incontinence due to sphincter insufficiency; - Post-surgical injection to avoid adhesions, particularly peritoneal; - Injection following presbyopia surgery using laser scleral incisions; - Injection into the vitreous cavity; - Injection during cataract surgery; - Injection into the genitals; - Injection for tissue spacing. [000259] More particularly, in cosmetic surgery, depending on its viscoelastic and remanence properties, the emulsion according to the invention may be used: to improve the hydration and quality of the skin by cutaneous mesotherapy of the face, neck, décolleté or hands. In this case, the product is injected using a needle with a diameter varying between 22 and 32G and lengths generally varying between 1 / 8" and V2". The composition may be injected either by hand or via automatic devices such as injector pens and / or guns. for tissue rejuvenation. In this case, the product is injected using a needle with a diameter varying between 22 and 32G and lengths generally varying between 1 / 8" and 1 / z". for filling fine, medium or deep wrinkles, and to be injected with fine diameter needles (27 Gauge to 30G most commonly, the lengths being generally 1 / 2"); as a volumizer with an injection either by needles of larger diameter, 25 to 27G Gauge for example, and longer (30 to 40 mm for example), or by cannulas of length mostly between 40 and 70 mm and diameter 22 to 25G; in this case, its cohesive nature will ensure its maintenance at the injection site. [000260] The gel, gelled emulsion or emulsion according to the invention also finds an important application in joint surgery and in dental surgery for the filling of periodontal pockets for example. [000261] These examples of use are in no way limiting, the gel, the gelled emulsion or the emulsion according to the present invention being more broadly intended for: - fill volumes; - generate spaces between certain tissues; - replace deficient physiological fluids; - Reshape any body area. [000262] The invention also relates to the process for preparing gels, gelled emulsions or emulsions according to the invention, characterized in that it comprises the following steps: a) Fat or fat derivative is provided, b) A hydrogel is provided, c) The hydrogel and the fat or fat derivative are mixed aseptically, d) The mixture is emulsified until an emulsion, a gelled emulsion or a homogeneous gel is obtained. [000263] In one embodiment, the hydrogel contains an active ingredient as previously defined. [000264] In one embodiment, an active ingredient is provided which is introduced at the time of mixing the hydrogel and the fat or fat derivative. [000265] The fat, the fat derivative, the hydrogel and the active ingredients are as previously defined. [000266] In different embodiments of the invention, the gel, gelled emulsion or emulsion comprising different hydrogels, different fat products or fat derivatives can be injected into the patient's body at different levels of anatomical depth, on different areas of the body and at different concentrations or dilutions. These different compositions and injection methods will be adapted according to the area to be treated and the different needs for remodeling or improving the trophicity of the treated areas. Thus, different gels, gelled emulsions or emulsions can be used at the same time or successively for the same area or for different areas of the body. [000267] The invention makes it possible to significantly improve the rheology of fat for lipofilling by making it more suitable for injection. The gels, gelled emulsions or emulsions obtained are stable and have a consistency close to, or equivalent to, that of mayonnaise. [000268] Gels, gelled emulsions or emulsions have great malleability allowing them to be injected via very small diameter cannulas which allows practitioners to be extremely precise and to limit the undesirable effects which are quite common in the case of fat injections for lipofilling alone. [000269] The use of an emulsion, a gelled emulsion or a gel according to the invention makes it possible to significantly reduce the appearance of post-operative bruising compared to the injection of fat for lipofilling alone. [000270] In addition, this malleability makes it easier for the surgeon to perform the procedure and makes it more fluid because the injectability of the emulsions is good. [000271] Finally, this malleability allows the surgeon to reshape different areas of the body. It is possible to modify the implantation area or the shape of the implant once it is injected. These post-injection modifications make it possible to obtain the desired effects more satisfactorily. [000272] The injection of the emulsion, the gelled emulsion or the gel according to the invention makes it possible to obtain visible effects on the skin, such as for example a remodeling effect or even an improvement in the radiance of the skin. [000273] The visible effects on the skin are still visible at least 3 months after the injection. [000274] The visible effects on the skin are still visible at least 6 months after the injection. [000275] The visible effects on the skin are still visible at least 12 months after the injection. [000276] The visible effects on the skin are still visible at least 18 months after the injection. [000277] The invention also relates to a kit for the preparation of an emulsion, a gelled emulsion or a gel of fat or fat derivative and hyaluronic acid comprising a cartridge (4) and at least 2 syringes. [000278] In one embodiment of the kit, the cartridge (4) comprises at least one hydrogel. [000279] In one embodiment the kit comprises at least 3 syringes. [000280] In one embodiment the kit comprises at least 4 syringes. [000281] In one embodiment the kit comprises at least 10 syringes. [000282] Kit 1: syringes 1 and 2 + cartridge 4 filled with hyaluronic acid. [000283] Syringe 1 (medium volume syringe) is empty or full of fatty tissue, cartridge 4 contains the hyaluronic acid gel (crosslinked or not) and syringe 2 (large volume syringe) is empty and its volume is equivalent to the addition of the volume of syringe 1 and cartridge 4 (VI + V4). 1. Use syringe 1 to collect the fat for lipofilling, or the previously prepared MICROFAT or NANOFAT (medium-sized syringe). 2. Take cartridge 4 pre-filled with hyaluronic acid and connect syringe 1 to cartridge 4 using Luer-Lock connectors 1a and 4a. 3. Add syringe 2 (large volume syringe VI + V4) to the second tip 4-b of cartridge 4 and operate pistons 1b and 2b of both syringes 1 and 2 using back and forth movements to create an emulsion between the fat for lipofilling and the hyaluronic acid gel. 4. After several back and forth movements (at least 5 movements), completely draw the emulsion into syringe 2 (large volume syringe). 5. Disconnect syringe 2 from the cartridge, the gel, gelled emulsion or emulsion contained in this syringe 2 is ready to be injected. 6. Fit a cannula onto syringe 2, tip 2a, to perform the injections. The choice of these cannulas is left to the surgeon's discretion depending on the area to be treated. [000284] Optional steps can be carried out to allow the incorporation of active ingredients into the gel, the gelled emulsion or the emulsion of hyaluronic acid and fat for lipofilling. These new steps can be incorporated at two separate times. Can be carried out before step 3: a) After several back and forth movements (at least 5 movements), completely draw up the gel, gelled emulsion or emulsion into syringe 2 (large volume syringe). b) Disconnect syringe 1 from tip 4a of the cartridge and connect syringe 5, containing the active ingredients, to this same cartridge on tip 4b. c) Empty the contents of syringe 5 into the cartridge, then operate the plungers 2b and 5b of syringes 2 and 5 to mix the gel, gelled emulsion or emulsion with the active ingredient. d) Completely draw the mixture into syringe 2 where Can be carried out after step 4: a) Disconnect syringe 2 from the cartridge. b) Connect together syringe 2, containing the gel, gelled emulsion or hyaluronic acid and fat emulsion for lipofilling, and syringe 5, containing the active ingredient, via a double Luer-Lock connector connected to tips 2a and 5a of each of the two syringes. c) Perform back and forth movements (at least 5 movements), to mix the gel, gelled emulsion or emulsion and the active ingredient by operating pistons 2b and 5b of each of the syringes. d) Completely draw the emulsion mixed with the active ingredient into syringe 2. e) Disconnect syringe 2, the gel, gelled emulsion or emulsion contained in this syringe 2 is ready to be injected. [000285] Kit 2: syringes 1, 2 and 3 + cartridge 4 [000286] Syringe 1 (medium volume syringe) is used to collect fat for lipofilling or transformed fat, syringe 3 (small volume syringe) contains hyaluronic acid gel (crosslinked or not), cartridge 4 and syringe 2 (large volume syringe) are empty. 1. Use syringe 1 to collect fat for lipofilling (medium size syringe). 2. Connect syringe 1 to empty cartridge 4 using connectors 1a and 4a. 3. Connect syringe 3 (small syringe), containing the HA gel, to the empty cartridge 4 using connectors 3a and 4b. 4. Fill the empty cartridge 4 with the contents of syringe 3 (HA gel). 5. Disconnect syringe 3 from tip 4b and connect syringe 2 (larger syringe VI + V4) to tip 4b using connector 2a. 6. Make back and forth movements on the pistons 1b and 2b, of the two syringes 1 and 2, to create an emulsion (at least 5 movements), 7. Completely fill syringe 2 with the contents of syringe 1 and cartridge 4. 8. Disconnect syringe 2 from the cartridge, the gel, gelled emulsion or emulsion contained in syringe 2 is ready to be injected. 9. Fit a cannula onto syringe 2, tip 2a, to perform the injections. The choice of these cannulas is left to the surgeon's discretion depending on the area to be treated. [000287] In one embodiment, a syringe 5 may be added to kit 1 or to kit 2, for example to incorporate an active ingredient as defined above. [000288] Optional steps can be carried out to allow the incorporation of active ingredients into the gel, the gelled emulsion or the hyaluronic acid and fat emulsion for lipofilling. These new steps can be incorporated at two separate times. Can be carried out after step 6: a) Completely fill syringe 3 with the contents of syringe 1 and cartridge 4. b) Disconnect syringe 3 and connect in its place, on the tip 4b of the cartridge, syringe 5 via tip 5a. c) Empty the contents of syringe 5 into cartridge 4. d) Actuate the pistons 2b and 5b of syringes 2 and 5 to make back and forth movements (at least 5 movements), to mix the gel, the gelled emulsion or the emulsion and the active ingredient. e) Completely fill syringe 2 with the contents of syringe 5 and cartridge 4. where Can be carried out after step 8: a) Disconnect syringe 2 from the cartridge. b) Connect together syringe 2, containing the gel, gelled emulsion or hyaluronic acid and fat emulsion for lipofilling, and syringe 5, containing the active ingredient, via a double Luer Lock connector, connected to tips 2a and 5a of each of the two syringes. c) Perform back and forth movements (at least 5 movements), to mix the gel, gelled emulsion or emulsion and the active ingredient by operating pistons 2b and 5b of each of the syringes. d) Completely draw up the gel, gelled emulsion or emulsion mixed with the active ingredient into syringe 2. e) Disconnect syringe 2, the emulsion contained in this syringe 2 is ready to be injected. [000289] Kit 3: 2 syringes (2) of 20 mL, 2 syringes (1) of 10 mL, 10 syringes (3) of 1 mL, all with or without Luer Lock, and the cartridge (4). [000290] In one embodiment, the two 20 mL syringes are used to collect fat from the patient, the two 10 mL syringes contain pure lipofilling fat or pure transformed fat (MICROFAT or NANOFAT), the 1 mL syringes are filled with the different compositions to be injected into the patient and the cartridge (4) contains the gel used to form the emulsions. 1. Use the two 20 mL syringes to collect fat from the patient. 2. The fat contained in the two 20 mL syringes is washed, then decanted or centrifuged to separate the different constituents and keep only the pure fat. 3. The fat phase is then introduced into one of the two 10 mL syringes. 4. Optionally, it is possible to collect 2 mL of pure fat using two 1 mL syringes 5. The two 10 mL syringes are used to prepare pure fat into fat for lipofilling or processed fat. 6. Both syringes are connected by their Luer Lock tips to a fat preparation device to obtain fat for lipofilling or transformed fat. 7. Once the fat for lipofilling or transformed fat is obtained, a portion of it is introduced into four 1 mL syringes. 8. The 10 mL syringe containing the remaining fat for lipofilling or processed fat is then connected to the cartridge (4) containing the gel via the Luer Lock tip and tip (4a), and a second 10 mL syringe is connected to the cartridge on the second (4b). 9. The contents of the cartridge are drawn into the syringe containing the fat for lipofilling or transformed fat and the emulsion is created by making back and forth movements between the two 10 mL syringes by activating their pistons (at least 5 movements). 10. After the emulsion is formed, it is drawn completely into the 10 mL syringe. 11. Four 1 mL syringes are then connected successively to the 10 mL syringe and filled with the emulsion, to have four syringes containing the gel, gelled emulsion or emulsion to be injected. 12. After these different steps, the practitioner has two syringes containing pure fat, 4 syringes containing fat for lipofilling or transformed fat and 4 syringes containing the gel, the gelled emulsion or the emulsion according to the invention. 13. Fit a cannula onto each of the syringes shown in point 12, using a Luer Lock tip, to carry out injections of the different compositions defined previously. The choice of these cannulas is left to the surgeon's discretion depending on the area to be treated. [000291] Presentation of the cartridge and the different emulsification devices [000292] In one embodiment, the cartridge is empty and it allows the mixing between the fat for lipofilling and the gel, consisting of at least one polysaccharide alone or in a mixture, free or crosslinked, to form the gel, the gelled emulsion or the emulsion according to the invention. [000293] In one embodiment, the cartridge contains only the gel consisting of at least one polysaccharide alone and / or in a mixture, free and / or crosslinked, and it allows the mixing between the fat for lipofilling and the gel to form the gel, the gelled emulsion or the emulsion according to the invention. [000294] In one embodiment, the cartridge allows static mixing between the fat for lipofilling and the gel, consisting of at least one polysaccharide alone or in a mixture, free or crosslinked, to form the gel, the gelled emulsion or the emulsion according to the invention. [000295] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling is made up of two tips (6), mixing cartridge (I) the gel by the presence of two parallel planes (7c) and (8c), one having a single central orifice (7d) and the second having several orifices on the periphery (8d). [000296] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel is made up of two tips (9) and (10), also forming the body of the mixing cartridge (II), in which a mixing cross (11) is incorporated. [000297] In one embodiment, the mixing cartridge (III), allowing static mixing between the fat for lipofilling and the gel, is made up of a tip (12), a connector (14), enclosing a mixing cross (15), a body (13) made up of a vertical plane (13c) having several orifices (13d). [000298] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of between 0.5 and 10 mL. [000299] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 0.5 mL. [000300] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 1 mL. [000301] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 2 mL. [000302] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 3 mL. [000303] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 4 mL. [000304] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 5 mL. [000305] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 6 mL. [000306] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 7 mL. [000307] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 8 mL. [000308] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 9 mL. [000309] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a volume of 10 mL. [000310] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a diameter of between 8 mm and 30 mm. [000311] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a diameter of 8 mm. [000312] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a diameter of 10 mm. [000313] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a diameter of 15 mm. [000314] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a diameter of 20 mm. [000315] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a diameter of 25 mm. [000316] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a diameter of 30 mm. [000317] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 45 mm and 100 mm. [000318] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 45 mm. [000319] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 50 mm. [000320] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 55 mm. [000321] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 60 mm. [000322] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 65 mm. [000323] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 70 mm. [000324] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 75 mm. [000325] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 80 mm. [000326] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 85 mm. [000327] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 90 mm. [000328] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 95 mm. [000329] In one embodiment, the cartridge allowing static mixing between the fat for lipofilling and the gel has a length of between 100 mm. DESCRIPTION OF FIGURES [000330] Figure 1 represents a cartridge (4) and 4 syringes (1), (2), (3) and (5). [000331] Figure 2 shows the overall view of an assembled mixing cartridge (I), this mixing cartridge (I) is made up of two identical tips (6), a body with a hole (7), and a perforated body (8). The different parts constituting the mixing cartridge (I) are fitted into each other. [000332] Figure 3 represents the sectional view of an assembled mixing cartridge (I), this view shows that the parts (7) and (8) are fitted into each other. [000333] Figure 4 shows the side view of a tip (6). These tips have a male Luer lock connector (6a), allowing the mixing cartridge (I) to be connected and locked onto a syringe. [000334] Figure 5 shows the sectional view of a tip (6). These tips (6) fit either into the perforated body (8), via a circular notch (6b) allowing the reduction in diameter (8b) of the perforated body (8) to be accommodated, or into the body with a hole (7), via a circular notch (6b) allowing the reduction in diameter (7b) of the perforated body (7) to be accommodated. [000335] Figure 6 represents the front view of a tip (6). [000336] Figure 7 shows the side view of the body with a hole (7), which can be connected on one side to a tip (6), by means of a reduction in the external diameter (7a). [000337] Figure 8 shows the sectional view of the body with a hole (7), which can be connected on one side to the perforated body (8), by means of a circular notch (7b). This part has a plane perpendicular to the walls (7c), pierced with an orifice parallel to the walls (7d). This orifice is placed on the side of the connection with a tip (6). [000338] Figure 9 represents the front view of the body with a hole (7), the orifice (7d) is located in the center of the plane perpendicular to the walls (7c). [000339] Figure 10 shows the side view of the perforated body (8), which can be connected on one side to a tip (6), by means of a reduction in the external diameter (8a), and on the other side to the body a hole (7), by means of a reduction in the external diameter (8b). [000340] Figure 11 represents the sectional view of the perforated body (8), this part has a plane perpendicular to the walls (8c), pierced with several orifices parallel to the walls (8d). These orifices are placed on the side of the reduction of the external diameter (8a) allowing the connection with a tip (6). [000341] Figure 12 represents the front view of the perforated body (8), the orifices (8d) are located on the periphery of the plane perpendicular to the walls (8c). Allowing for alternation, and no preferential path, for the movement of fluids within the mixing cartridge (I), thus creating a static mixture of the constituents of the gels according to the invention. [000342] Figure 13 shows the overall view of an assembled mixing cartridge (II), this mixing cartridge (II) is made up of two separate bodies, the body (10) and the body (9). The different parts constituting the mixing cartridge (II) are fitted into each other. [000343] Figure 14 represents the sectional view of an assembled mixing cartridge (II), this view shows that the two parts, (9) and (10), forming the body of the cartridge are fitted into one another and that the device contains a mixing cross (11). [000344] Figure 15 represents the side view of the body (10). This body (10) has a male Luer lock connector (10a), allowing the connection and locking of the mixing cartridge (II) on a syringe. The body (10) fits into the body (9) via a reduction in the external diameter (10b). [000345] Figure 16 represents the sectional view of the body (10). [000346] Figure 17 represents the front view of the body (10). [000347] Figure 18 shows the side view of the body (9). This body (9) has a male Luer lock connector (9a), allowing the mixing cartridge (II) to be connected and locked onto a syringe. [000348] Figure 19 represents the sectional view of the body (9). The body (9) fits into the body (10) via a circular notch (9b) allowing the reduction in diameter (10b) of the body (10) to be accommodated. [000349] Figure 20 represents the front view of the body (9). [000350] Figure 21 represents the side view of the cross (11), this cross promotes the static mixing of the constituents of the gels according to the invention. This mixing cross (11) is enclosed in the mixing cartridge (II), within the space formed by the assembly of the body (10) and the body (9). [000351] Figure 22 represents the overall view of the cross (11). [000352] Figure 23 represents the front view of the cross (11). [000353] Figure 24 shows the overall view of an assembled mixing cartridge (III), this mixing cartridge (III) is made up of a nozzle (12), a perforated body (13), and a connector (14). The different parts constituting the mixing cartridge (III) are fitted into each other. [000354] Figure 25 represents the sectional view of an assembled mixing cartridge (III), this view shows that the different parts constituting it, (12)- (13) and (14), are fitted into one another and that the device contains a mixing cross (15) at the level of the connection (14). [000355] Figure 26 shows the side view of the tip (12). This tip has a male Luer lock connector (12a), allowing the mixing cartridge (III) to be connected and locked onto a syringe. [000356] Figure 27 shows the sectional view of the end piece (12). The end piece (12) fits into the perforated body (13) via a circular notch (12b) to accommodate the reduction in diameter (13b) of the perforated body (13). [000357] Figure 28 represents the front view of the tip (12). [000358] Figure 29 shows the side view of the perforated body (13), which can be connected on one side to the end piece (12), by means of a reduction in the external diameter (13a), and on the other side to the connector (14), by means of a reduction in the external diameter (13b). [000359] Figure 30 represents the sectional view of the perforated body (13), this part has a plane perpendicular to the walls (13c), perforated with several parallel orifices to the walls (13d). These holes are placed on the side (13a) of the connection with the end piece (12). [000360] Figure 31 represents the front view of the perforated body (13), the orifices (13d) are located on the periphery of the plane perpendicular to the walls (13c) allowing for alternation, and no preferential path, for the movement of the fluids within the mixing cartridge (III), thus creating a static mixture of the constituents of the gels according to the invention. [000361] Figure 32 shows the side view of the cross (15), this cross promotes the static mixing of the constituents of the gels according to the invention. This mixing cross (15) is enclosed in the mixing cartridge (III), within the space formed by the assembly of the perforated body (13) and the connector (14). [000362] Figure 33 represents the overall view of the cross (15). [000363] Figure 34 represents the front view of the cross (15). [000364] Figure 35 shows the side view of the connector (14). This connector (14) has a male Luer lock connector (14a), allowing the mixing cartridge (III) to be connected and locked onto a syringe. [000365] Figure 36 shows the sectional view of the connector (14). The connector (14) fits into the perforated body (13) via a circular notch (14b) to accommodate the reduction in diameter (13b) of the perforated body (13). [000366] Figure 37 represents the front view of the connector (14). [000367] The following examples are given to illustrate the invention. EXAMPLES: Example 1: Hyaluronic acid gels [000368] A commercial non-crosslinked hyaluronic acid gel, the product Stylage® Hydro (VIVACY) and a commercial crosslinked hyaluronic acid gel comprising a local anesthetic, the product Juvederm Ultra® 2 (ALLERGAN), were used for the preparation of the fat and hyaluronic acid emulsions according to the invention. These commercial hyaluronic acid gels are available in 1 mL syringes. Example 2: Process for recovering the fat used for the preparation of the fat emulsion. [000369] Fatty tissue, called lipofilling fat, was harvested during surgery with the appropriate consent of the donor, preferably from the abdomen or knees. [000370] The fat collection was carried out following standard surgical techniques under anesthesia according to a protocol involving in particular identification of the area of ​​the body to be collected, making an incision in the collection area followed or not by infiltration with Klein serum, collection of the fat for lipofilling using a specific Tonnard cannula of the Tulip ® brand and transfer of the fat from the cannula to a sterile syringe under vacuum using back and forth movements in the tissues and fan-shaped movements of the cannula to avoid bleeding and obtain a regular appearance after collection. [000371] The choice of material used for the sample as well as its technical characteristics is left to the surgeon's discretion depending on the area to be treated. [000372] The grease-filled syringe is ready to use or can be stored in the cold before use. Example 3: Process for preparing a fat emulsion for lipofilling [000373] Recovered fat for lipofilling is collected using a sterile 5 mL syringe equipped with a Luer lock system. [000374] This sterile syringe is connected to one of the inlets of a sterile 3-way valve or to one of the inlets of a sterile double Luer lock connector, while to one of the other inlets is connected an empty sterile 5 mL syringe equipped with the Luer lock system. [000375] In order to obtain a homogeneous emulsion based solely on fat for lipofilling, rapid back and forth movements of the pistons between the two sterile syringes connected to each other by the 3-way valve or by the double Luer lock connector are carried out. At least 40 back and forth movements are necessary to obtain a satisfactory emulsion of fat for lipofilling. Example 4: Process for preparing a fat emulsion for lipofilling and hyaluronic acid according to the invention [000376] 4 mL of recovered fat for lipofilling is collected using a sterile 5 mL syringe equipped with a Luer lock system. [000377] This sterile syringe is connected to one of the inlets of a sterile 3-way valve or to one of the inlets of a sterile double Luer lock connector, while to one of the other inlets is connected a syringe containing 1 mL of hyaluronic acid gel. [000378] The hyaluronic acid gel is then introduced into the sterile syringe containing the fat for lipofilling. [000379] The syringe containing the hyaluronic acid gel is replaced by an empty sterile 5 mL syringe equipped with a Luer lock system. [000380] In order to obtain a homogeneous emulsion based on fat for lipofilling and hyaluronic acid, rapid back and forth movements of the pistons between the two sterile syringes connected to each other by the 3-way valve or by the double Luer lock connector are carried out. At least 40 back and forth movements are necessary to obtain a satisfactory emulsion of fat for lipofilling and hyaluronic acid. [000381] In a variant, the homogeneous emulsion is obtained using the kit comprising the cartridge as defined above. Example 5: Storage stability of a fat emulsion for lipofilling and hyaluronic acid according to the invention. [000382] The stability of a fat emulsion for lipofilling and hyaluronic acid prepared according to the method of Example 2 from the product Stylage® Hydro was monitored visually during horizontal storage on a table at 20°C, 2 hours and 4 hours after its preparation. [000383] The stability of a fat emulsion for lipofilling prepared according to the method of Example 1 was also evaluated in parallel according to the same protocol. [000384] The results of this stability study are described in Table 1. Table 1 [000385] A pure fat emulsion for lipofilling degrades rapidly as indicated by the formation of two phases after 2 hours of storage at room temperature. [000386] The fat emulsion for lipofilling and hyaluronic acid according to the invention is stable at room temperature for at least 4 hours. [000387] The stability of the fat emulsion for lipofilling and hyaluronic acid according to the invention offers flexibility and comfort to the surgeon in the context of its use during a surgical procedure. Example 6: Injectability of fat emulsions for lipofilling and hyaluronic acid according to the invention [000388] The injectability of a fat emulsion for lipofilling and hyaluronic acid prepared according to the method of Example 2 from the product Stylage® Hydro and a fat emulsion for lipofilling and hyaluronic acid prepared according to the method of example 2 from the product Juvederm Ultra® 2 was evaluated through 27G and 25G cannulas from freshly prepared emulsions and after 4h30 of storage at 20°C. [000389] For comparison, the injectability of a freshly prepared fat emulsion for lipofilling was evaluated through 27G and 25G cannulas. [000390] The injectability results are shown in Table 2. Table 2 [000391] The results obtained show that the fat emulsions for lipofilling and hyaluronic acid according to the invention allow the surgeon to use cannulas of a smaller size than those which can be used for the injection of a pure fat emulsion for lipofilling. [000392] The fat emulsions for lipofilling and hyaluronic acid according to the invention can still be injected with small cannulas at least 4.5 hours after their preparation, which provides comfort and flexibility in terms of use during a surgical procedure. Example 7: Appearance of fat emulsions for lipofilling and hyaluronic acid according to the invention after passage through a cannula [000393] The stability of fresh emulsions according to the invention and 4.5 hours after their preparation was evaluated by visual observation of the deposit obtained after passing through a 25G cannula. [000394] The emulsions tested are identical to those of example 4. [000395] The observation results of these different emulsions are presented in Table 3. Table 3 [000396] The fat emulsions for lipofilling and hyaluronic acid according to the invention have better resistance after passing through a cannula than the pure fat emulsion for lipofilling, even after storage for 4.5 hours at room temperature. [000397] The emulsions of fat for lipofilling and hyaluronic acid according to the invention have a malleability close to a gel, this characteristic is different from that of fat for lipofilling alone. The emulsions obtained according to the invention behave like a modeling clay, which is a different property from fat for lipofilling alone. Example 8: Rheological properties of fat emulsions for lipofilling and hyaluronic acid according to the invention [000398] The viscoelastic properties were measured using an AR2000 rheometer from TA instrument. The measurements are carried out at 25 °C with a 2 ° 40 mm conical geometry using a frequency sweep from 0.08 to 5 Hz with a deformation of 0.8%. [000399] The viscoelastic properties were measured for a fat emulsion for lipofilling prepared according to Example 1 and for an emulsion of fat for lipofilling and hyaluronic acid prepared according to Example 2 from the product Stylage® Hydro. [000400] The results of the measurements of G' and Tan 5 at 1 Hz, as well as the cut-off frequency of the G' and G", / "cut-off curves, of the different samples studied are presented in Table 4 below. Table 4 [000401] The rheological properties of the fat emulsion for lipofilling and hyaluronic acid according to the invention prepared from the Stylage® Hydro product are not affected by passage through a 25G size cannula. [000402] It can be noted that the fat emulsion for lipofilling and hyaluronic acid according to the invention prepared from the product Stylage® Hydro has a Tan 5 value close to that of the commercial hyaluronic acid gel Stylage® Hydro. [000403] The rheological properties of the fat emulsion for lipofilling and hyaluronic acid according to the invention prepared from the product Stylage® Hydro are much more interesting than those of the pure fat emulsion for lipofilling. Example 9: Microscopic analysis of fat emulsion for lipofilling and hyaluronic acid according to the invention. [000404] The microscopic analyses were carried out using an Axio scope Al optical microscope from Zweiss, equipped with Filtrex software and with x20 magnification. [000405] Three types of samples were analyzed under a microscope: a sample of a fat sample for lipofilling, a sample of a fat emulsion for lipofilling prepared according to example 1, a sample of a fat emulsion for lipofilling and hyaluronic acid according to the invention prepared according to example 2 from the product Stylage® Hydro. [000406] The results of the various microscopic observations of the samples are presented in Table 5 below. Table 5 [000407] The fat and hyaluronic acid emulsion according to the invention has a more regular appearance with small fat globules incorporated in a hyaluronic acid matrix. Example 10: Comparative clinical study [000408] Two groups A and B of patients are formed. A contains 40 patients and B contains 40, making 80 patients in total. [000409] Group A is injected for facial rejuvenation with an emulsion of fat for lipofilling and hyaluronic acid while group B is injected for facial rejuvenation with fat for lipofilling. [000410] For each patient in group A, an emulsion of fat for lipofilling taken from the patient and hyaluronic acid is prepared according to the method of example 4, the hyaluronic acid used being the product Stylage® Hydro, with a concentration of 14 mg / g in a mannitol phosphate buffer (VIVACY Laboratory), the fat being washed and decanted fat for lipofilling of the MICROFAT type and the hyaluronic acid:fat volume ratio being 1:4. [000411] For each patient in group B, the fat for lipofilling is taken from the patient and is of the MICROFAT type. [000412] On D0, each patient has fat taken from the stomach area in accordance with the protocol described in example 2. [000413] The injection at the facial level will be carried out using a 25G Steriglide cannula from TSK brand after having made a pre-hole using a 23G Steriglide pre-hole needle from TSK brand. [000414] The practitioner in charge of the injection evaluates the volume injected per hemiface and assesses the ease of injection of the product using the injectability score. This score of 0 to 3 is assessed as follows: 0: injection impossible: the product does not come out. 1: Poor injectability: need to apply very high force to eject the product from the syringe, irregular product ejection flow and cannula clogging 2: medium injectability: need to apply high force to eject the product from the syringe, product ejection flow with jerks 3: good injectability: medium to low force to eject the product, smooth and continuous injection, without jolts. [000415] The person in charge of administration also assesses the malleability of the product when setting up the product using a 2-level scale: 0: the product is not malleable: it cannot be deformed and remains in a block or disperses when massaged or under digital pressure in an uncontrollable manner 1: the product is malleable: it remains in place and under massage or digital pressure. [000416] On D+1, the practitioner in charge of the injection evaluates the adverse effects in terms of occurrence and severity, while the patient assesses the rejuvenation effect using a patient satisfaction score of 1 to 3: 1: unsatisfactory rejuvenation effect 2: moderately satisfactory rejuvenation effect 3: satisfactory rejuvenation effect 4: very satisfactory rejuvenation effect, intention to start again [000417] The results are summarized in table 6 below: Table 6 [000418] These examples show that the gels according to the invention, composed of fat for lipofilling and hyaluronic acid, make it possible to obtain results of rejuvenation much more satisfactory than fat injections for lipofilling alone. [000419] The gels according to the invention make it possible to improve the malleability of fat for lipofilling. [000420] The gels according to the invention make it easier to inject fat for lipofilling because there is no problem of obstruction of the cannulas, unlike tests with fat for lipofilling alone. [000421] In addition, the injections of gels according to the invention make it possible to significantly limit the occurrence of post-injection side effects. Indeed, it appears that side effects, such as bruises, are observed in only 5% of cases with the gels according to the invention, compared to 50% in the case of fat injections for lipofilling alone. Example 11: In vitro injectability study on 10 samples [000422] Mixture of 4 cc of fat for lipofilling, MICROFAT type or NANOFAT type, with 1 cc of Stylage® Hydro product, which is a hyaluronic acid gel with a concentration of 14 mg / g in a mannitol phosphate buffer sold by VIVACY Laboratories, the hyaluronic acid:fat volume ratio being 1:4. [000423] Manual injectability test with TSK Steriglide brand cannulas and BD brand 10 cc Luer-Lock syringes. [000424] The choice of cannulas is made from among the cannulas dedicated to the injection of filler products (22G to 27G), that is to say for sizes smaller than the lipofilling cannulas (19-21G) usually used during surgical interventions. [000425] The practitioner assesses injectability blindly and sets an injectability score using the following injectability scale: 0: injection impossible: the product does not come out. 1: Poor injectability: need to apply very high force to eject the product from the syringe, irregular product ejection flow and cannula clogging 2: medium injectability: need to apply high force to eject the product from the syringe, product ejection flow with jerks 3: good injectability: medium to low force to eject the product, smooth and continuous injection, without jolts [000426] The results are summarized in Table 7 below: Table 7 [000427] For the same cannula size, the injectability is at least identical, or even more often, better with the subject of the invention. This makes it possible, on the one hand, to inject with smaller cannulas, therefore less traumatic for the patient, and on the other hand, to facilitate the practitioner's gesture because the gestures are more fluid and more precise. Example 12: Non-comparative clinical study 45 cases [000428] The gel studied in this example is made up of NANOFAT, resulting from the transformation of lipofilling fat, and the product Stylage® Hydro, which is a hyaluronic acid gel with a concentration of 14 mg / g in a mannitol phosphate buffer sold by Laboratoires VIVACY, the hyaluronic acid:fat volume ratio being 1:4. [000429] A non-comparative study of 45 clinical cases was carried out over a period of 2 years, combining a mixture of 4cc of NANOFAT and 1 cc of Stylage® Hydro product. [000430] On D0, each patient has fat taken from the stomach area, then injected into the face using a 25G cannula in the malar area for facial rejuvenation. Each patient is injected on each side of the face and therefore undergoes 2 injection procedures. [000431] 90 injection procedures are therefore carried out. [000432] The results are summarized in the following Table 8: Table 8 [000433] This clinical study has demonstrated that this new method of skin rejuvenation gives satisfaction to all patients treated, a large majority of whom declare themselves very satisfied. In addition, the effect is still visible more than a year after the procedure was carried out. Finally, side effects are rare, not very widespread and mild.

Claims

DEMANDS

1. Emulsion, gelled emulsion or gel comprising a hydrogel and fat or a fat derivative.

2. Emulsion, gelled emulsion or gel according to claim 1, characterized in that the fat is lipofilling fat or MICROFAT, i.e. fat consisting of fatty tissue taken by means of a small diameter cannula which has not undergone any transformation or alteration.

3. Emulsion, gelled emulsion or gel according to claim 1, characterized in that the fat is NANOFAT, i.e., fat consisting of fatty tissue taken from the body which has been subjected to mechanical action with knives to liquefy it followed by filtration to obtain a very fluid substance enriched in cells.

4. Emulsion, gelled emulsion or gel according to any one of the preceding claims, characterized in that it further comprises an active ingredient selected from the group consisting of local anesthetics, vitamin C derivatives, anti-inflammatories, antioxidants, and mixtures thereof.

5. Emulsion, gelled emulsion or gel according to any one of the preceding claims, characterized in that the hydrogel is made up of at least one polysaccharide selected from the group consisting of hyaluronic acid, keratin, heparin, cellulose, cellulose derivatives (in particular hydroxypropylcellulose, hydroxypropylmethylcellulose, ethylmethylcellulose, carboxymethylcellulose), alginic acid, xanthan gum, carrageenan, chitosan, chondroitin, heparosan, and their biologically acceptable salts, alone or in mixture.

6. Emulsion, gelled emulsion or gel according to claim 6, characterized in that said polysaccharide is hyaluronic acid or one of its salts, alone or in mixture.

7. Emulsion, gelled emulsion or gel according to claim 7, characterized in that said polysaccharide is hyaluronic acid in the form of sodium or potassium salt

8. Emulsion, gelled emulsion or gel according to any one of claims 6 to 8, characterized in that said polysaccharide is non-crosslinked hyaluronic acid or one of its salts, alone or in mixture.

9. Emulsion, gelled emulsion or gel according to any one of claims 6 to 8, characterized in that said polysaccharide is cross-linked hyaluronic acid or one of its salts, alone or in mixture.

10. Emulsion, gelled emulsion or gel according to claim 10, characterized in that said polysaccharide is cross-linked hyaluronic acid or one of its salts, alone or in mixture, and in that said crosslinking is carried out by means of at least one bifunctional crosslinking agent being butanedioldiglycidyl ether (BDDE) or 1,2,7,8-diepoxyoctane

11. Emulsion, gelled emulsion or gel according to any one of claims 6 to 11, characterized in that the molecular mass mw of at least one hyaluronic acid is within a range of 0.01 MDa and 5 MDa.

12. Emulsion, gelled emulsion or gel according to any one of claims 6 to 12, characterized in that the concentration of hyaluronic acid [HA] in the hydrogel is between 2 mg / g and 50 mg / g of total weight of said hydrogel.

13. Emulsion, gelled emulsion or gel according to any one of the preceding claims, characterized in that the hydrogel is sterilized, i.e. that after its preparation it undergoes a sterilization step, said sterilization step being carried out by heat, by moist heat, by gamma(y) radiation, by accelerated electron beam (electron-beam), or by sterilizing filtration (0.22 pm) in the case of hydrogels based on non-crosslinked hyaluronic acid.

14. Emulsion, gelled emulsion or gel according to any one of the preceding claims, characterized in that the hydrogel / fat or fat derivative volume ratio is between 0.5 / 4.5 and 2 / 3.

15. A method for preparing an emulsion, a gelled emulsion or a gel according to any one of the preceding claims, characterized in that it comprises the following steps: a) Fat or a fat derivative is available, b) A hydrogel is available, c) The hydrogel and the fat or fat derivative are mixed aseptically, d) The mixture is emulsified until a homogeneous emulsion, gelled emulsion or gel is obtained.

16. Kit for the preparation of an emulsion, a gelled emulsion or a gel according to any one of the preceding claims characterized in that it comprises a cartridge (4) and at least 2 syringes.

17. Kit according to claim 15, characterized in that the cartridge (4) comprises at least one hydrogel.

Images